Egetis Therapeutics (EGTX) Q3 2026 earnings summary

Executive summary

• FDA approved EMCITATE on Sep 28 as the first and only U.S. treatment for peripheral thyrotoxicosis in patients with MCT8 deficiency; U.S. launch began Oct 27.

• Q3 revenue rose 24% YoY at CER to MSEK 21.5, while the quarterly loss widened to MSEK 147.0.

• A Nov 4 agreement to sell the FDA-granted PRV for USD 190M is expected to provide a substantial non-dilutive cash contribution; former RTTI owners are entitled to ~50% of net proceeds.

Financial highlights

• Q3 revenue was MSEK 21.5 vs. 17.4, up 24% YoY at CER; Jan-Sep revenue was MSEK 52.3 vs. 44.6, up 17% at CER.

• Q3 operating loss was MSEK 135.0 vs. 76.5; Jan-Sep operating loss was MSEK 337.2 vs. 219.6.

• Net loss was MSEK 147.0 in Q3 vs. 82.4 and MSEK 350.4 for Jan-Sep vs. 222.8; EPS was SEK -0.3 and -0.8, respectively.

• Q3 operating expenses rose to MSEK 136.9 from 80.0, mainly on U.S. launch preparation and operational build-out; Jan-Sep marketing and sales costs reached MSEK 123.6 vs. 66.1.

• Gross profit was MSEK 1.9 in Q3 vs. 3.5 and MSEK 5.2 for Jan-Sep vs. 8.2; COGS included a one-time MSEK 4.0 EMC approval milestone in Q3.

Outlook and guidance

• 2026 priorities: execute the U.S. EMCITATE launch, optimize European pricing and reimbursement while continuing launch, and finalize tiratricol’s RTH-beta development plan.

• Japan NDA submission for EMCITATE is expected in 2027; preparations are ongoing using data from the global clinical program.

• Regulatory interactions and development planning for tiratricol in RTH-beta are in preparation; the indication remains investigational.